Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Andrea M. Glaspell
Observed name:
Andrea Glaspell
Institutions:
Nationwide Children's Hospital,
Abigail Wexner Research Institute
Observed institutions:
Nationwide Children's Hospital,
Abigail Wexner Research Institute
ORCID:
0000-0002-7035-9305
Observed ORCID:
0000-0002-7035-9305
OpenAlex ID:
A5019885893
Leveraging gene therapy to achieve long-term continuous or controllable expression of biotherapeutics
2022
·
Timothy P. Cripe
, Brian Hutzen
, et al.
·
Science Advances
·
25
Trabectedin promotes oncolytic virus antitumor efficacy, viral gene expression, and immune effector function in models of bone sarcoma
2024
·
Emily M. Ringwalt
, Mark A. Currier
, et al.
·
Molecular Therapy Oncology
·
12
Development of VNX-101, an adeno-associated virus with less immunogenicity and efficient long-term expression of a CD19 T cell engager
2025
·
Mark A. Currier
, Allen Reha
, et al.
·
Molecular Therapy — Methods & Clinical Development
·
3
PDF
Myelomodulatory treatments augment the therapeutic benefit of oncolytic viroimmunotherapy in murine models of malignant peripheral nerve sheath tumors
2024
·
Siddhi N. Paudel
, Brian J. Hutzen
, et al.
·
Frontiers in Immunology
·
2
Abstract 1087: Synergistic mechanisms against pediatric bone sarcoma models: Trabectedin enhances oncolytic virotherapy intratumoral spread and antitumor immune activation
2024
·
Emily Ringwalt
, Mark Currier
, et al.
·
Cancer Research
·
2
Trabectedin decreases myeloid resistance to improve the efficacy of anti-PD1 immunotherapy and delay glioma malignant progression
2026
·
Matthew Nazzaro
, Elaine R. Mardis
, et al.
·
Molecular Therapy Oncology
·
1
Using Gene Therapy to Solve Challenges with CAR-T Cell Immunotherapy: Lead Selection and Preclinical Development of an Adeno-Associated Virus with Reduced Immunogenicity Exhibiting Efficient and Long-Term Expression of an Anti-CD19 T-Cell Engager
2024
·
Mark A Currier
, Allen Reha
, et al.
·
Blood
709 Chemotherapy agent trabectedin demonstrates immunomodulatory properties that improve efficacy of anti-PD1 immunotherapy and delay glioma malignant progression
2024
·
Matthew Nazzaro
, Alessandro Canella
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
Corrigendum: Myelomodulatory treatments augment the therapeutic benefit of oncolytic viroimmunotherapy in murine models of malignant peripheral nerve sheath tumors
2024
·
Siddhi N. Paudel
, Brian J. Hutzen
, et al.
·
Frontiers in Immunology
Trabectedin modulates the glioma innate and adaptive immune microenvironment in vivo
2024
·
Matthew Nazzaro
, Prajwal Rajappa
, et al.
·
The Journal of Immunology
Show more works
View as search
Works count:
10
Citation count:
45
H-index:
3
I10-index:
2
Year
Topic
Type